Stay updated on Flotetuzumab in PIF/ER AML Clinical Trial
Sign up to get notified when there's something new on the Flotetuzumab in PIF/ER AML Clinical Trial page.

Latest updates to the Flotetuzumab in PIF/ER AML Clinical Trial page
- Check7 days agoNo Change Detected
- Check14 days agoChange DetectedThe study record page now shows a 403 Forbidden error, indicating access is blocked. The additions include the HTML structure of a 403 page (title, header, and footer) rather than substantive study details.SummaryDifference21%

- Check21 days agoNo Change Detected
- Check35 days agoChange DetectedThe page now shows revision v3.6.6, replacing the previous v3.6.5. This reflects a small deployment update with no documented changes to the study details or eligibility criteria.SummaryDifference0.0%

- Check56 days agoChange DetectedThe study page now displays a server error page with a basic HTML frame. This replaces the full study record and related content on the page.SummaryDifference20%

- Check71 days agoChange DetectedThe page revision tag was updated from v3.6.3 to v3.6.4, signaling a small backend/content update with no visible changes to the study details shown to users.SummaryDifference0.0%

- Check92 days agoChange DetectedPage build updated from v3.6.2 to v3.6.3. This reflects a new release of the page rather than content changes.SummaryDifference0.0%

- Check99 days agoChange DetectedThe page’s revision tag was updated from v3.6.0 to v3.6.2, indicating a new release of the page’s software. This update likely represents minor fixes or improvements behind the scenes rather than user-facing content changes.SummaryDifference0.0%

Stay in the know with updates to Flotetuzumab in PIF/ER AML Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Flotetuzumab in PIF/ER AML Clinical Trial page.